乌司他丁联合奥曲肽治疗重症急性胰腺炎56例

目的观察联合应用乌司他丁（UTI）和奥曲肽治疗重症急性胰腺炎（SAP）的疗效。方法将56例重症急性胰腺炎患者按就诊顺序随机分为治疗组（UTI＋奥曲肽）和对照组（奥曲肽），每组28例，观察治疗前后患者的临床症状、体征、血尿淀粉酶和血清中白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF—α）水平。结果治疗组可显著改善SAP患者的临床症状体征、降低血尿淀粉酶及血清IL-6、TNF—α水平，提高临床治愈率及总有效率，优于对照组（P〈0．05或0．01）。结论UTI和奥曲肽联合治疗可降低SAP患者的炎症性细胞因子，明显提高重症急性胰腺炎的疗效。

Clinical research of 56 cases with severe acute pancreatitis in treatment by combining ulinastatin and octreotide

Objective To observe the effects of ulinastatin（UTI）and octreotide in the treatment of severe acute pancreatitis （SAP）. Methods Fifty - six cases SAP patients were randomly divided into treatment group（ treated with ulinastatin and otreotid ） and control group（ treated with otreotid）, 28 cases of each group. The clinical symptoms, physical sign and lab exams such as amylaseinurine, hyperamylasemia, IL- 6, TNF-α were detected before and after treatment. Results Compared with control group, the treatment group can greatly improve SAP patients＇clinical symptoms, physical sign, the cure rate and the total effective rate, reduce the levels of amylaseinurine, hyperamylasemia, and the serum levels of IL - 6, TNF - α. So the effect in treatment group was much better than that in control group, there were significantly different （ P 〈 0. 05 or 0. 01 ）. Conclusion Combined UTI and octreotide can treat SAP patients by reducing the serum levels of IL - 6, TNF - α, significantly improve clinical efficacy.